All News

Corona.COVID_.jpg

EULAR and ACR COVID19 Guidelines: Similarities Provide Reassurance

Rachel Tate, DO

In difficult times, it's reassuring to reflect on the similarities that bring us together. In the case of the EULAR and ACR COVID19 guidelines as discussed at #EULAR2020 by Drs.

Read Article
TNR Biosimilars

TNR Grand Rounds - Update on Biosimilars

Jack Cush, MD

This week's Tuesday Nite Rheumatology featured Dr Jonathan Kay (U Mass) who gave an update on Biosimilars and took questions the subject. The program was moderated by Dr. Jack Cush.

Read Article
joint.pain_.hand_.PIP_.jpg

Noninflammatory Pain Persists in RA Despite Treatment

RheumNow

Almost one-third of patients with new-onset rheumatoid arthritis (RA) reported persistent unacceptable pain after 21 months of combination therapy, according to a study by Swedish researchers.A total of 29% of patients continued to have unacceptable pain.

Read Article
podcast logo

RheumNow Podcast - Rheumatic Patients with COVID (5.29.20)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Cytokine storm

TNR Grand Rounds - Cytokine Storm Syndromes

Jack Cush, MD

This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. The program was moderated by Dr. Jack Cush.

Read Article
COVID.virus_.corona.jpg (keep)

Boston and Wuhan Report Rheum COVID Patients at Risk for Respiratory Failure

Jack Cush, MD

Two current reports from Boston and Wuhan describe cohorts of COVID-19 (+) rheumatic disease patients who generally do well but appear to have a higher risk of pulmonary involvement.

Read Article
lupus_0.jpg

Hydroxychloroquine Improves Survival in Lupus

Jack Cush, MD

Hydroxychloroquine (HCQ) has dominated the news in recent weeks, because of poor outcomes reported when used in COVID patients. Yet, a recent report reaffirms what rheumatologists have known for years - that HCQ use is associated with better outcomes in systemic lupus erythematosus, including survival.  

Read Article
infx.pneumonia.jpg

Low Risk of COVID-19 Pneumonia in Rheumatic Patients

Jack Cush, MD

A current letter in the Annals of Rheumatic Disease details the rheumatic disease patient cohort outcomes from the University of Siena, Italy showing only 2 cases of COVID-19 among 859 patients treated with tsDMARDs and bDMARDs.

Read Article
Integrated safety analysis of filgotinib treatment for RA from 7 clinical trials: 4,057 patients, VTE risk looks very reassuring #EULAR2020 @RheumNow https://t.co/Ld2tpu7UT5 https://t.co/sZqadeUTh8

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)
And another one! No association of MTX with worsening of ILD in this study by Men-Vazquez et al. #EULAR2020 https://t.co/X7C6KyC29L
Richard Conway RichardPAConway ( View Tweet)
#EULAR2020 ABST#OP0012 German RABBIT registry show TNFi has less risk for venothrombolic events HR 0.53 (95% CI 0.33-0.86) compared to csDMARD in RA. Age > 65 years, CRP > 5 mg/L increases risk for VTE, no differences with steroids or smoking status. @RheumNow https://t.co/Hkv6T7pl9f
k dao KDAO2011 ( View Tweet)
#EULAR2020 Plenary Abstr#OP0016 Brilliant study showed how gut microbiota dysbiosis may trigger RA in high risk people (+CCP w/o Sx) using fecal transplantation in a mouse model to trigger collagen induced arthritis @rheumnow Healthy vs. preclin RA vs. RA microbiota specimen: https://t.co/ZITCAcmuXh
k dao KDAO2011 ( View Tweet)
After seeing the results of the NORD-STAR early RA trial, would you start a newly diagnosed, treatment naive RA patient on: #EULAR2020 @RheumNow

k dao KDAO2011 ( View Tweet)

#EULAR2020 OP0020: RABBIT 5500 pt study of all DMARDS/biologics, IL-6 inh may be the best to improve fatigue seen in RA patients @rheumnow https://t.co/VJW8MwMamM
k dao KDAO2011 ( View Tweet)
How long should you keep pts on TCZ for GCA after remission has been achieved? @RheumNow #eular2020

k dao KDAO2011 ( View Tweet)

#EULAR2020 Dr. Kimme Hyrich reviews the EULAR #COVID19 Registry "Most individuals with rheumatic diseases receiving immunosuppressive therapies recover from COVID19" @rheumnow https://t.co/EdVLUMyHhF
k dao KDAO2011 ( View Tweet)
#EULAR2020 panel on #COVID19 spec. situatns: 1. German regtry: very few preg rheum pts w/CV19; cases mild. 2. No info how CV19 affects APS 3. Very few ped rheum cases of CV19- cases mild; outcomes sim to gen peds pop 4. Most rheum pts w/CV19 good prognosis @rheumnow https://t.co/LQVdzJKCgu
k dao KDAO2011 ( View Tweet)
10 ReA pt study out of India reviewing ETN-b found that all pts (previously on ETN) responded to biosimilar med without new safety signals. Further details are here on abstract #AB0632 https://t.co/lRA2IDvU4H #EULAR2020 @RheumNow https://t.co/QyhwBzBBH3

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Does TCZ actually fix GCA? @nihrheumatology cohort w serial PET/CT q6m: FDG uptake (PETVAS) reduces longitudinally over 2y but does not normalise, w rebound on TCZ cessation Ongoing reductions in year 2? GCA doesn't sleep. @KQuinnRheum @petercgrayson OP0144 #EULAR2020 @RheumNow https://t.co/aczQbONcNc
David Liew drdavidliew ( View Tweet)
BTK inhib (fenbrutinib-FEN) effective in #RA. In a 12 wk RCT, 480 MTX-IR pts Rx either PBO, adalimumab or FEN (50 mg or 150 mg/d). ACR50 resp was PBO 15%; ADA 36%; FEN 50mg 18%, 150 qd 28%, 200 mg bid 35%. FEM NO effx on myeloid & B cell biomarkers. https://t.co/JIb4FtiOQG

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×